An Imaging Biomarker of Tumor-Infiltrating Lymphocytes to Risk-Stratify Patients With HPV-Associated Oropharyngeal Cancer
Abstract
Human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) has excellent control rates compared to nonvirally associated OPSCC. Multiple trials are actively testing whether de-escalation of treatment intensity for these patients can maintain oncologic equipoise while reducing treatment-related toxicity. We have developed OP-TIL, a biomarker that characterizes the spatial interplay between tumor-infiltrating lymphocytes (TILs) and surrounding cells in histology images. Herein, we sought to test whether OP-TIL can segregate stage I HPV-associated OPSCC patients into low-risk and high-risk groups and aid in patient selection for de-escalation clinical trials.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 29, 2021
- Source ID
- 10.1093/jnci/djab215
Entities
People
- Anant Madabhushi
- Can Koyuncu
- Cheng Lu
- Christina Buzzy
- David J. Adelstein
- Deborah Chute
- Farhoud Faraji
- Germán Corredor
- James Sheridan Lewis, Jr.
- Justin A. Bishop
- Kailin Yang
- Kaustav Bera
- Kim A Ely
- Lester D. R. Thompson
- Mitra Mehrad
- Mojgan Mokhtari
- Patricia D Castro
- Paula Toro
- Pingfu Fu
- Shlomo A. Koyfman
- Vlad Sandulache
- Wade L Thorstad
Organizations
- Baylor College of Medicine
- Case Western Reserve University
- Cleveland Clinic
- Kaiser Permanente
- Louis Stokes Cleveland VA Medical Center
- Michael E. DeBakey Veterans Affairs Medical Center in Houston
- National Cancer Institute
- National Center for Research Resources
- National Heart, Lung, and Blood Institute
- National Institute of Biomedical Imaging and Bioengineering
- UC San Diego Health System
- United States Department of Defense
- United States Department of Veterans Affairs
- University of Texas at Austin
- Vanderbilt University
- Wallace H. Coulter Foundation
- Washington University in St. Louis